European Medicines Agency

A new regulation and registry covering investigational medicinal products mandates reporting and supports multinational trials.

The European Medicines Agency emphasizes that the benefits of the jab in protecting against COVID-19 still far outweigh the risks.

Rollouts of the shot have ground to a halt following reports of blood clots, but health authorities say that these fears are unfounded and vaccination programs should continue.

The recent move of the European Medicines Agency from London to Amsterdam is a reflection of the city’s vibrant life sciences and health sector and supporting industries.

As Britain’s departure date from the European Union approaches, drugmakers are preparing for potential changes to regulatory procedures and border controls.

A coin toss decides the agency’s post-Brexit home once it departs from London.

In recent years, the US Food and Drug Administration has approved more drugs and in less time than the European Medicines Agency.

Researchers raise concerns related to collaboration, funding, and regulatory decisions.

The European Medicines Agency is preparing for a new policy that will release rarely-seen clinical trial reports for independent scrutiny.  

The European Medicines Agency has recommended that farmers stop using the antibiotic colistin prophylactically, citing human health concerns.

The pharmaceutical industry has agreed to share data from clinical trials with researchers, patients, and the public.

Backed by two leading medical journals, researchers propose a new plan to publish clinical trial data that pharmaceutical companies often try to bury.
 

A court ruling that stops the European Medicines Agency from releasing data from two US companies calls into question the agency’s push for transparency.

The European Commission approves the Western hemisphere’s first gene therapy, aimed at correcting a lipid-processing disorder.

The FDA approves drugs faster and earlier than regulatory agencies in other countries.

The European Medicines Agency revised its policy on conflicts of interest in response to concerns regarding its ability to conduct independent evaluations.